welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Novo Biosciences achieves major milestones in moving trodusquemine into clinical trials
Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy (DMD). Trodusquemine is a repurposed drug candidate that has already been shown to be well tolerated by patients.
“Trodusquemine holds significant potential for the treatment of some of our most devastating diseases,” said Kevin Strange, Ph.D., Novo’s CEO. “Our recent progress on the path toward clinical trials gives hope to the millions of patients who face limited treatment options.”
rareRelated
-
Evaluation of Muscle miRNA as Biomarkers in DystrophinopathiesDuchenne muscular dystrophy (DMD), cause...
-
Care Complications: Chest Painhttps://www.youtube.com/watch?v=8qkR-EZ2...
-
FDA and NIH to loosen oversight of gene therapy developmentCiting the need to safely expedite the d...
-
Duchenne Muscular Dystrophy Clinical TrialThe primary objective of this investigat...
-
Future Clinical And Biomarker Development For SMT C1100, The First Utrophin Modulator To Enter Clinical Trials For D...Objective: To progress SMT C1100, Summi...
-
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201Wave Life Sciences Ltd., a biotechnology...
-
Evox Therapeutics wins funding from Duchenne UK to explore exosome-mediated delivery of dystrophinEvox Therapeutics Ltd, a leading exosome...
